RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nugenerex Immuno-Oncology Stock

Nugenerex Immuno-Oncology Revenue 2024

Nugenerex Immuno-Oncology Revenue

0 USD

Ticker

NUGX

ISIN

US67053X1028

WKN

A2P853

In 2024, Nugenerex Immuno-Oncology's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Nugenerex Immuno-Oncology Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2020--
2019--
2018700-

Nugenerex Immuno-Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nugenerex Immuno-Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nugenerex Immuno-Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nugenerex Immuno-Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nugenerex Immuno-Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nugenerex Immuno-Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nugenerex Immuno-Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nugenerex Immuno-Oncology’s growth potential.

Nugenerex Immuno-Oncology Revenue, EBIT and net profit per share

DateNugenerex Immuno-Oncology RevenueNugenerex Immuno-Oncology EBITNugenerex Immuno-Oncology Net Income
20200 undefined-730,000 undefined-1.59 M undefined
20190 undefined-390,000 undefined-1.11 M undefined
2018700,000 undefined420,000 undefined-170,000 undefined

Nugenerex Immuno-Oncology stock margins

The Nugenerex Immuno-Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nugenerex Immuno-Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nugenerex Immuno-Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nugenerex Immuno-Oncology's sales revenue. A higher gross margin percentage indicates that the Nugenerex Immuno-Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nugenerex Immuno-Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nugenerex Immuno-Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nugenerex Immuno-Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nugenerex Immuno-Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nugenerex Immuno-Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nugenerex Immuno-Oncology Margin History

Nugenerex Immuno-Oncology Gross marginNugenerex Immuno-Oncology Profit marginNugenerex Immuno-Oncology EBIT marginNugenerex Immuno-Oncology Profit margin
20200 %0 %0 %
20190 %0 %0 %
20180 %60 %-24.29 %

Nugenerex Immuno-Oncology Aktienanalyse

What does Nugenerex Immuno-Oncology do?

Nugenerex Immuno-Oncology Inc is an emerging company in cancer research and treatment. It was founded in 2003 by Dr. William J. Garner and is headquartered in San Diego, California. The origins of Nugenerex Immuno-Oncology lie in the exploration of RNA interference (RNAi) and the development of therapeutics for the treatment of cancer and other diseases. In 2006, the company made a groundbreaking discovery by developing a novel technology called "Blank Gene Therapy," which has the potential to revolutionize cancer treatment. Nugenerex Immuno-Oncology is an innovative biotechnology company focused on developing cancer treatments based on the patient's own immune system. The company has a division for cancer research and development and a division for medical services, combining scientific expertise with a global presence. In its research and development division, Nugenerex Immuno-Oncology focuses on developing novel immunological therapies based on "Blank Gene Therapy." These therapies aim to stimulate the patient's immune system to recognize and destroy cancerous cells. In addition to research and development, the company also offers medical services. The medical services division provides patients and healthcare providers worldwide with access to the latest cancer treatments and clinical trials. By collaborating with doctors and hospitals worldwide, patients gain access to innovative cancer treatments tailored to their specific case. The company has several products in development, including a novel immunotherapeutic called "Enrichin." It is based on "Blank Gene Therapy" and aims to stimulate the patient's immune system to recognize and destroy tumor-like cells. Additionally, the company is working on the development of antibody therapeutics and oncolytic viruses to destroy cancer cells. Nugenerex Immuno-Oncology has also formed a partnership with a leading pharmaceutical company to develop therapeutics for multiple sclerosis and other autoimmune diseases. In summary, Nugenerex Immuno-Oncology is an emerging company in cancer research and treatment, focusing on novel immunological therapies. With its products, services, and global presence, it aims to improve the lives of cancer patients worldwide. Nugenerex Immuno-Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Nugenerex Immuno-Oncology's Sales Figures

The sales figures of Nugenerex Immuno-Oncology originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Nugenerex Immuno-Oncology’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Nugenerex Immuno-Oncology's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Nugenerex Immuno-Oncology’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Nugenerex Immuno-Oncology stock

How much revenue did Nugenerex Immuno-Oncology generate this year?

Nugenerex Immuno-Oncology has achieved a revenue of 0 USD this year.

How much was the turnover of the company Nugenerex Immuno-Oncology compared to the previous year?

The revenue of Nugenerex Immuno-Oncology has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Nugenerex Immuno-Oncology?

The revenue of Nugenerex Immuno-Oncology is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Nugenerex Immuno-Oncology measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Nugenerex Immuno-Oncology so important for investors?

The revenue of Nugenerex Immuno-Oncology is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Nugenerex Immuno-Oncology pay?

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Nugenerex Immuno-Oncology?

The current dividend yield of Nugenerex Immuno-Oncology is .

When does Nugenerex Immuno-Oncology pay dividends?

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nugenerex Immuno-Oncology?

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

What is the dividend of Nugenerex Immuno-Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nugenerex Immuno-Oncology located?

Nugenerex Immuno-Oncology is assigned to the '-' sector.

Wann musste ich die Aktien von Nugenerex Immuno-Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nugenerex Immuno-Oncology from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Nugenerex Immuno-Oncology pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Nugenerex Immuno-Oncology in the year 2023?

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

In which currency does Nugenerex Immuno-Oncology pay out the dividend?

The dividends of Nugenerex Immuno-Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nugenerex Immuno-Oncology

Our stock analysis for Nugenerex Immuno-Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nugenerex Immuno-Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.